Celia E. Eckert is a distinguished legal professional currently serving as the General Counsel at Xencor, Inc., a biopharmaceutical company focused on the discovery and development of engineered monoclonal antibody therapeutics. With a robust background in corporate law and a keen understanding of the biotechnology industry, Eckert has become an integral part of Xencor's leadership team. She joined the company in 2013 and has since played a pivotal role in guiding its legal strategy, ensuring compliance, and facilitating key business transactions that have propelled Xencor's growth and success. Prior to her tenure at Xencor, Eckert amassed extensive experience in the legal field, working with several high-profile law firms where she specialized in corporate governance, securities law, and mergers and acquisitions. Her expertise in navigating complex legal landscapes has been crucial in supporting Xencor's innovative research and development efforts. Eckert's strategic vision and dedication to excellence have not only bolstered Xencor's legal framework but also contributed significantly to its corporate culture and overall mission to advance healthcare through cutting-edge science. In her role as General Counsel, Celia E. Eckert oversees all legal matters at Xencor, including intellectual property management, regulatory compliance, and corporate governance. Her leadership has been instrumental in securing partnerships and collaborations that enhance Xencor's portfolio and drive its scientific advancements. Eckert's contributions have been recognized within the industry, earning her a reputation as a trusted advisor and a forward-thinking executive. Her commitment to fostering a culture of integrity and innovation continues to be a driving force behind Xencor's achievements in the biopharmaceutical sector.